Michael L Steinberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4450951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer and Prostatic Diseases, 2023, 26, 207-209.	3.9	8
2	Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial. Radiotherapy and Oncology, 2022, 170, 14-20.	0.6	28
3	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiotherapy and Oncology, 2022, 166, 1-7.	0.6	9
4	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. Clinical Genitourinary Cancer, 2022, 20, e94-e103.	1.9	1
5	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	7.1	18
6	Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. Radiotherapy and Oncology, 2022, 167, 203-210.	0.6	20
7	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiotherapy and Oncology, 2022, 167, 226-232.	0.6	7
8	Landscape of mortality during and within thirty days after non-palliative radiotherapy across eleven major cancer types. Radiotherapy and Oncology, 2022, 167, 308-316.	0.6	2
9	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	10.7	68
10	A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers, 2022, 14, 939.	3.7	5
11	Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial Journal of Clinical Oncology, 2022, 40, 255-255.	1.6	24
12	Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel. Frontiers in Oncology, 2022, 12, 853246.	2.8	3
13	Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. Advances in Radiation Oncology, 2022, 7, 100944.	1.2	1
14	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	1.9	19
15	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
16	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer and Prostatic Diseases, 2021, 24, 135-139.	3.9	11
17	Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213.	0.6	24
18	The Declining Residency Applicant Pool: A Multi-Institutional Medical Student Survey to Identify Precipitating Factors. Advances in Radiation Oncology, 2021, 6, 100597.	1.2	13

#	Article	IF	CITATIONS
19	Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals. Journal of the American College of Radiology, 2021, 18, 312-317.	1.8	2
20	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology, 2021, 4, 327-330.	5.4	3
21	Provider-Level Variation in Treatment Planning of Radiation Oncology Procedures in the United States. JCO Oncology Practice, 2021, 17, OP.20.00441.	2.9	3
22	Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease. JAMA Network Open, 2021, 4, e2034074.	5.9	9
23	Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients. Cancers, 2021, 13, 1910.	3.7	9
24	The landscape of mortality during or within 30 days after non-palliative radiotherapy across 11 major cancer types Journal of Clinical Oncology, 2021, 39, 6570-6570.	1.6	1
25	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer, 2021, 21, 538.	2.6	29
26	Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology. Practical Radiation Oncology, 2021, 11, e256-e262.	2.1	2
27	Weak Magnetic Fields Enhance the Efficacy of Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100645.	1.2	3
28	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial networkâ€based data augmentation. Medical Physics, 2021, 48, 3262-3372.	3.0	11
29	National variation in the delivery of radiation oncology procedures in the nonâ€facilityâ€based setting. Cancer Medicine, 2021, 10, 4734-4742.	2.8	1
30	Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial. Cancers, 2021, 13, 2802.	3.7	11
31	Clinical outcomes of stereotactic magnetic resonance imageâ€guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. Cancer Medicine, 2021, 10, 5897-5906.	2.8	20
32	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Network Open, 2021, 4, e2115312.	5.9	12
33	Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. International Journal of Radiation Oncology Biology Physics, 2021, 110, 731-737.	0.8	27
34	Evaluation of T2-Weighted MRI for Visualization and Sparing of Urethra with MR-Guided Radiation Therapy (MRgRT) On-Board MRI. Cancers, 2021, 13, 3564.	3.7	11
35	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. European Urology, 2021, 80, 142-146.	1.9	12
36	A Practical Guide for Navigating the Design, Build, and Clinical Integration of Electronic Patient-Reported Outcomes in the Radiation Oncology Department. Practical Radiation Oncology, 2021, 11. e376-e383.	2.1	6

#	Article	IF	CITATIONS
37	Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT. Applied Radiation Oncology, 2021, 10, 33-40.	0.5	0
38	Simultaneous radiosurgery for multiple brain metastases: technical overview of the UCLA experience. Radiation Oncology, 2021, 16, 221.	2.7	10
39	The Model of an ASTRO Servant Leader. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1120-1121.	0.8	0
40	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
41	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	5.9	16
42	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. European Urology, 2020, 77, 3-10.	1.9	18
43	Clinical Outcomes Using Magnetic Resonance–Guided Stereotactic Body Radiation Therapy in Patients With Locally Advanced Cholangiocarcinoma. Advances in Radiation Oncology, 2020, 5, 189-195.	1.2	31
44	Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411.	1.2	6
45	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology, 2020, 77, 201-208.	1.9	37
46	Re: Aminsharifi et al., Major Complications and Adverse Events Related to the Injection of the SpaceOAR Hydrogel System Before Radiotherapy for Prostate Cancer: Review of the Manufacturer and User Facility Device Experience Database (From: Aminsharifi A, Kotamarti S, Silver D, et al., J Endourol) Tj ETQqC) 0 0 2;1 BT /(Overlock 10 T
47	Comparison of Clinical Outcomes Stratified by Target Delineation for Patients Undergoing Stereotactic Body Radiotherapy for Spinal Metastases. World Neurosurgery, 2020, 136, e68-e74.	1.3	3
48	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32.	0.6	19
49	Cost Effectiveness of External Beam Radiation Therapy versus Percutaneous Image-Guided Cryoablation for Palliation of Uncomplicated Bone Metastases. Journal of Vascular and Interventional Radiology, 2020, 31, 1221-1232.	0.5	9
50	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. Advances in Radiation Oncology, 2020, 5, 1334-1341.	1.2	1
51	Time-Driven Activity-Based Costing Analysis of Telemedicine Services in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 108, 430-434.	0.8	9
52	Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. Frontiers in Oncology, 2020, 10, 539.	2.8	29
53	Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose–volume histogram using ensemble machine learning. Radiotherapy and Oncology, 2020, 148, 181-188.	0.6	9
54	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 917-926.	0.8	11

#	Article	IF	CITATIONS
55	Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT. JCO Oncology Practice, 2020, 16, e1378-e1385.	2.9	24
56	Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. Physics in Medicine and Biology, 2020, 65, 175006.	3.0	38
57	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Frontiers in Oncology, 2020, 10, 786.	2.8	3
58	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 930-935.	0.8	12
59	The Timeliness Initiative: Continuous Process Improvement for Prompt Initiation of Radiation Therapy Treatment. Advances in Radiation Oncology, 2020, 5, 1014-1021.	1.2	11
60	Time-Driven Activity-Based Costing Comparison of Stereotactic Radiosurgery to Multiple Brain Lesions Using Single-Isocenter Versus Multiple-Isocenter Technique. International Journal of Radiation Oncology Biology Physics, 2020, 108, 999-1007.	0.8	9
61	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clinical Cancer Research, 2020, 26, 1829-1836.	7.0	63
62	Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer Journal of Clinical Oncology, 2020, 38, 211-211.	1.6	0
63	Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer Journal of Clinical Oncology, 2020, 38, 208-208.	1.6	0
64	The intraprostatic immune balance after prostate SBRT in patients Journal of Clinical Oncology, 2020, 38, 339-339.	1.6	0
65	Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials Journal of Clinical Oncology, 2020, 38, 327-327.	1.6	1
66	Evaluation of a centralized toxicity view in the electronic health record (EHR) for physician-recorded Common Terminology Criteria for Adverse Events (CTCAE) Journal of Clinical Oncology, 2020, 38, 296-296.	1.6	0
67	Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). Advances in Radiation Oncology, 2019, 4, 738-747.	1.2	6
68	Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2019, 105, 149-154.	0.8	9
69	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 628-636.	0.8	20
70	Key considerations when reviewing subsequent primary cancers following radiotherapy. Lancet Oncology, The, 2019, 20, e291.	10.7	1
71	Assessment of Differences in Clinical Activity and Medicare Payments Among Female and Male Radiation Oncologists. JAMA Network Open, 2019, 2, e190932.	5.9	21
72	Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. British Journal of Radiology, 2019, 92, 20181001.	2.2	7

#	Article	IF	CITATIONS
73	Evaluation of Sex Distribution of Industry Payments Among Radiation Oncologists. JAMA Network Open, 2019, 2, e187377.	5.9	26
74	Patient perspectives and treatment regret after deâ€escalated chemoradiation for human papillomavirusâ€positive oropharyngeal cancer: Findings from a phase II trial. Head and Neck, 2019, 41, 2768-2776.	2.0	5
75	Impact of Open Access to Physician Notes on Radiation Oncology Patients: Results from an Exploratory Survey. Practical Radiation Oncology, 2019, 9, 102-107.	2.1	8
76	If It Seems Too Good to Be True…. International Journal of Radiation Oncology Biology Physics, 2019, 103, 305-307.	0.8	3
77	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open, 2019, 2, e188006.	5.9	221
78	Training and Education Requirements for Authorized Users of Therapeutic Radiopharmaceuticals: Changes Under Consideration for 10CFR35.390 and Their Potential Impact. Journal of the American College of Radiology, 2019, 16, 1572-1576.	1.8	2
79	Fast, Low-Dose Megavoltage-Topogram Localization on TomoTherapy: Initial Clinical Experience With Mesothelioma Patients. Practical Radiation Oncology, 2019, 9, 373-380.	2.1	1
80	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. JAMA Oncology, 2019, 5, 91.	7.1	27
81	Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. Urology, 2019, 126, 89-95.	1.0	12
82	Psychological safety and near miss events in radiation oncology Journal of Clinical Oncology, 2019, 37, 231-231.	1.6	1
83	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Cleason Score 9-10 Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 896.	7.4	252
84	The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. Cancer, 2018, 124, 1673-1681.	4.1	30
85	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	5.0	81
86	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1154-1161.	1.3	35
87	A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 101, 564-573.	0.8	12
88	Patientâ€reported qualityâ€ofâ€life outcomes after deâ€escalated chemoradiation for human papillomavirusâ€positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer, 2018, 124, 521-529.	4.1	21
89	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clinical Breast Cancer, 2018, 18, e205-e218.	2.4	5
90	⁶⁸ Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	5.0	226

#	Article	IF	CITATIONS
91	First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology, 2018, 1, 378-385.	5.4	4
92	Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiotherapy and Oncology, 2018, 129, 319-325.	0.6	43
93	Accelerated 3D <scp>bSSFP</scp> imaging for treatment planning on an <scp>MRI</scp> â€guided radiotherapy system. Medical Physics, 2018, 45, 2595-2602.	3.0	10
94	Respiratory motion-resolved, self-gated 4D-MRI using Rotating Cartesian K-space (ROCK): Initial clinical experience on an MRI-guided radiotherapy system. Radiotherapy and Oncology, 2018, 127, 467-473.	0.6	19
95	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 883-888.	0.8	10
96	Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 44-52.	0.8	31
97	Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. Cureus, 2018, 10, e2324.	0.5	17
98	Stereotactic Magnetic Resonance-guided Online Adaptive Radiotherapy for Oligometastatic Breast Cancer: A Case Report. Cureus, 2018, 10, e2368.	0.5	8
99	Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer. Cureus, 2018, 10, e2442.	0.5	6
100	Magnetic Resonance-guided Inter-fraction Monitoring Opens Doors to Delivering Safer Reirradiation: An Illustrative Case Report and Discussion. Cureus, 2018, 10, e2479.	0.5	6
101	MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer. Cureus, 2018, 10, e2360.	0.5	2
102	Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. British Journal of Radiology, 2017, 90, 20160739.	2.2	43
103	Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Cleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017:71:766–73. European Urology, 2017, 72. e123-e124.	1.9	2
104	Treatment trends for patients with brain metastases: Does practice reflect the data?. Cancer, 2017, 123, 2274-2282.	4.1	27
105	Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. Radiotherapy and Oncology, 2017, 123, 133-138.	0.6	12
106	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 803-811.	10.7	261
107	In Reply to Scott. International Journal of Radiation Oncology Biology Physics, 2017, 98, 217.	0.8	0
108	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology, 2017, 107, 171-177.	1.0	3

#	Article	IF	CITATIONS
109	Magnetic resonance imaging guided reirradiation of recurrent and second primary head and neck cancer. Advances in Radiation Oncology, 2017, 2, 167-175.	1.2	28
110	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1045-1052.	0.8	12
111	Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. Gynecologic Oncology, 2017, 144, 21-27.	1.4	12
112	Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 516-525.	0.8	22
113	Location Matters: Stage I Non–Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes. Clinical Lung Cancer, 2017, 18, e137-e142.	2.6	21
114	High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy, 2017, 16, 299-305.	0.5	18
115	Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?. Cancer, 2017, 123, 531-532.	4.1	0
116	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy, 2017, 16, 1106-1112.	0.5	19
117	Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation. Radiotherapy and Oncology, 2017, 124, 455-461.	0.6	37
118	Gaps in Radiation Therapy Awareness: Results From an Educational Multi-institutional Survey of US Internal Medicine Residents. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1153-1161.	0.8	16
119	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Research and Treatment, 2017, 166, 145-156.	2.5	1
120	Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2017, 71, 766-773.	1.9	83
121	Online Adaptive Radiation Therapy: Implementation of a New Process of Care. Cureus, 2017, 9, e1618.	0.5	77
122	Radiation therapy in the management of breast cancer brain metastases: the impact of receptor status on treatment response, intracranial recurrence, and survival. Journal of Radiation Oncology, 2016, 5, 401-409.	0.7	0
123	Technical Note: Dosimetric effects of couch position variability on treatment plan quality with an MRI-guided Co-60 radiation therapy machine. Medical Physics, 2016, 43, 4514-4519.	3.0	Ο
124	The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy. British Journal of Radiology, 2016, 89, 20150963.	2.2	17
125	Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Journal of Thoracic Oncology, 2016, 11, 1319-1325.	1.1	16
126	Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 946-955.	0.8	13

#	Article	IF	CITATIONS
127	Utilizing timeâ€driven activityâ€based costing to understand the short―and longâ€ŧerm costs of treating localized, lowâ€risk prostate cancer. Cancer, 2016, 122, 447-455.	4.1	123
128	A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator–based stereotactic body radiotherapy for central early-stage nonâ^'small cell lung cancer. Medical Dosimetry, 2016, 41, 87-91.	0.9	31
129	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Practical Radiation Oncology, 2016, 6, 268-275.	2.1	27
130	High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. International Journal of Radiation Oncology Biology Physics, 2016, 94, 667-674.	0.8	101
131	In Regard to Mariados etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 936-937.	0.8	2
132	4ï€ Noncoplanar Stereotactic Body Radiation Therapy for Head-and-Neck Cancer: Potential to Improve Tumor Control and Late Toxicity. International Journal of Radiation Oncology Biology Physics, 2015, 91, 401-409.	0.8	62
133	A Fork in the Road: Choosing the Path of Relevance. International Journal of Radiation Oncology Biology Physics, 2015, 92, 214-216.	0.8	8
134	Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 91, 832-839.	0.8	17
135	Dependence of Achievable Plan Quality onÂTreatment Technique and Planning Goal Refinement: A Head-and-Neck Intensity Modulated Radiation Therapy Application. International Journal of Radiation Oncology Biology Physics, 2015, 91, 817-824.	0.8	6
136	Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer. Practical Radiation Oncology, 2015, 5, 257-262.	2.1	24
137	The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer, 2015, 90, 230-233.	2.0	22
138	Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. British Journal of Radiology, 2015, 88, 20150658.	2.2	5
139	Dosimetric feasibility of magnetic resonance imagingâ€guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. Practical Radiation Oncology, 2015, 5, 350-356.	2.1	8
140	In Regard to Bauman et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1162-1163.	0.8	7
141	Feasibility of magnetic resonance imaging–guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator–based intensity modulated radiation therapy. Practical Radiation Oncology, 2015, 5, 330-337.	2.1	28
142	Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma. Practical Radiation Oncology, 2015, 5, 366-373.	2.1	11
143	The International Cancer Expert Corps: A Unique Approach for Sustainable Cancer Care in Low and Lower-Middle Income Countries. Frontiers in Oncology, 2014, 4, 333.	2.8	29
144	Current Status and Recommendations for the Future ofÂResearch, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. International Journal of Radiation Oncology Biology Physics, 2014, 88, 11-17.	0.8	26

#	Article	IF	CITATIONS
145	Choosing Wisely: The American Society for Radiation Oncology's Top 5 list. Practical Radiation Oncology, 2014, 4, 349-355.	2.1	102
146	Value: A Framework for Radiation Oncology. Journal of Clinical Oncology, 2014, 32, 2864-2870.	1.6	47
147	Feasibility of prostate robotic radiation therapy on conventional C-arm linacs. Practical Radiation Oncology, 2014, 4, 254-260.	2.1	38
148	The overthrow of the (evidence) hierarchy. Practical Radiation Oncology, 2011, 1, 81-82.	2.1	3
149	Correspondence. Practical Radiation Oncology, 2011, 1, 139.	2.1	0